Author:
Ribeiro Johanne Pereira,Gluud Christian,Storm Maja Rosenberg Overby,Storebø Ole Jakob
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Cortese S, Coghill D, Fegert JM, Mattingly GW, Rohde LA, Wong ICK, Faraone SV (2024) ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines. Eur Child Adolesc Psychiatry 33(5):1605–1608. https://doi.org/10.1007/s00787-024-02443-5
2. Pereira Ribeiro J, Lunde C, Gluud C, Simonsen E, Storebø OJ (2022) Methylphenidate denied access to the WHO List of Essential Medicines for the second time. BMJ Evidence-Based Medicine. Advance online publication. https://doi.org/10.1136/bmjebm-2021-111862
3. Storebø OJ, Gluud C (2021) Methylphenidate for ADHD rejected from the WHO essential Medicines List due to uncertainties in benefit-harm profile. BMJ Evidence-Based Med 26(4):172–175. https://doi.org/10.1136/bmjebm-2019-111328
4. World Health Organization, WHO Expert Committee on Selection and Use of Essential Medicines (2021) The selection and use of essential medicines: Report of the, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children). World Health Organization. www.who.int/publications/i/item/9789240041134
5. World Health Organization (2021b) Decision on methylphenidate: https://list.essentialmeds.org/recommendations/1200